Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

AIMD vs DBVT vs ALKS vs AEYE

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AIMD
Ainos, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$8M
5Y Perf.-97.7%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-61.1%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+68.7%
AEYE
AudioEye, Inc.

Software - Application

TechnologyNASDAQ • US
Market Cap$100M
5Y Perf.-66.2%

AIMD vs DBVT vs ALKS vs AEYE — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AIMD logoAIMD
DBVT logoDBVT
ALKS logoALKS
AEYE logoAEYE
IndustryBiotechnologyBiotechnologyBiotechnologySoftware - Application
Market Cap$8M$1712.35T$5.90B$100M
Revenue (TTM)$113K$0.00$1.56B$40M
Net Income (TTM)$-15M$-168M$153M$-3M
Gross Margin82.7%65.4%78.3%
Operating Margin-126.7%12.3%-7.9%
Forward P/E24.8x
Total Debt$12M$22M$70M$721K
Cash & Equiv.$4M$194M$1.12B$5M

AIMD vs DBVT vs ALKS vs AEYELong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AIMD
DBVT
ALKS
AEYE
StockJan 21May 26Return
Ainos, Inc. (AIMD)1002.3-97.7%
DBV Technologies S.… (DBVT)10038.9-61.1%
Alkermes plc (ALKS)100168.7+68.7%
AudioEye, Inc. (AEYE)10033.8-66.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: AIMD vs DBVT vs ALKS vs AEYE

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ALKS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. AEYE also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
AIMD
Ainos, Inc.
The Secondary Option

AIMD lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT is the #2 pick in this set and the best alternative if momentum is your priority.

  • +110.4% vs AIMD's -35.4%
Best for: momentum
ALKS
Alkermes plc
The Defensive Pick

ALKS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.

  • Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
  • Beta 1.06, current ratio 3.55x
  • 9.8% margin vs AIMD's -132.3%
  • Beta 1.06 vs AIMD's 2.54, lower leverage
Best for: sleep-well-at-night and defensive
AEYE
AudioEye, Inc.
The Income Pick

AEYE is the clearest fit if your priority is income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 2.29
  • Rev growth 14.5%, EPS growth 30.6%, 3Y rev CAGR 10.5%
  • 102.2% 10Y total return vs ALKS's -11.0%
  • 14.5% revenue growth vs DBVT's -100.0%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthAEYE logoAEYE14.5% revenue growth vs DBVT's -100.0%
Quality / MarginsALKS logoALKS9.8% margin vs AIMD's -132.3%
Stability / SafetyALKS logoALKSBeta 1.06 vs AIMD's 2.54, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs AIMD's -35.4%
Efficiency (ROA)ALKS logoALKS5.4% ROA vs DBVT's -89.0%

AIMD vs DBVT vs ALKS vs AEYE — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AIMDAinos, Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
AEYEAudioEye, Inc.
FY 2024
Enterprise
100.0%$15M

AIMD vs DBVT vs ALKS vs AEYE — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLALKSLAGGINGDBVT

Income & Cash Flow (Last 12 Months)

ALKS leads this category, winning 4 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AIMD's -132.3%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
RevenueTrailing 12 months$113,037$0$1.6B$40M
EBITDAEarnings before interest/tax-$10M-$112M$212M-$504,000
Net IncomeAfter-tax profit-$15M-$168M$153M-$3M
Free Cash FlowCash after capex-$5M-$151M$392M$2M
Gross MarginGross profit ÷ Revenue+82.7%+65.4%+78.3%
Operating MarginEBIT ÷ Revenue-126.7%+12.3%-7.9%
Net MarginNet income ÷ Revenue-132.3%+9.8%-7.6%
FCF MarginFCF ÷ Revenue-41.2%+25.1%+5.5%
Rev. Growth (YoY)Latest quarter vs prior year+28.2%+7.9%
EPS Growth (YoY)Latest quarter vs prior year-93.9%+91.5%-4.1%+29.0%
ALKS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

AEYE leads this category, winning 2 of 3 comparable metrics.
MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
Market CapShares × price$8M$1712.35T$5.9B$100M
Enterprise ValueMkt cap + debt − cash$16M$1712.35T$4.9B$96M
Trailing P/EPrice ÷ TTM EPS-1.12x-0.76x24.76x-32.36x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple17.25x
Price / SalesMarket cap ÷ Revenue403.55x4.00x2.49x
Price / BookPrice ÷ Book value/share1.07x0.66x3.28x20.91x
Price / FCFMarket cap ÷ FCF12.28x
AEYE leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

ALKS leads this category, winning 8 of 9 comparable metrics.

ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIMD's 0.77x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs AIMD's 2/9, reflecting strong financial health.

MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
ROE (TTM)Return on equity-119.4%-130.2%+8.8%-47.8%
ROA (TTM)Return on assets-58.8%-89.0%+5.4%-9.5%
ROICReturn on invested capital-39.8%+18.9%-42.4%
ROCEReturn on capital employed-50.0%-145.7%+14.2%-17.7%
Piotroski ScoreFundamental quality 0–92474
Debt / EquityFinancial leverage0.77x0.13x0.04x0.15x
Net DebtTotal debt minus cash$8M-$172M-$1.0B-$5M
Cash & Equiv.Liquid assets$4M$194M$1.1B$5M
Total DebtShort + long-term debt$12M$22M$70M$721,000
Interest CoverageEBIT ÷ Interest expense-19.79x-189.82x32.30x-2.79x
ALKS leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

AEYE leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $61 for AIMD. Over the past 12 months, DBVT leads with a +110.4% total return vs AIMD's -35.4%. The 3-year compound annual growth rate (CAGR) favors AEYE at 6.4% vs AIMD's -55.6% — a key indicator of consistent wealth creation.

MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
YTD ReturnYear-to-date-0.3%+4.9%+25.3%-18.7%
1-Year ReturnPast 12 months-35.4%+110.4%+16.5%-27.9%
3-Year ReturnCumulative with dividends-91.3%+19.7%+14.5%+20.6%
5-Year ReturnCumulative with dividends-99.4%-69.1%+60.9%-60.2%
10-Year ReturnCumulative with dividends-97.0%-87.0%-11.0%+102.2%
CAGR (3Y)Annualised 3-year return-55.6%+6.2%+4.6%+6.4%
AEYE leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

ALKS leads this category, winning 2 of 2 comparable metrics.

ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than AIMD's 2.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs AIMD's 38.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
Beta (5Y)Sensitivity to S&P 5002.54x1.26x1.06x2.29x
52-Week HighHighest price in past year$4.50$26.18$36.60$16.39
52-Week LowLowest price in past year$1.26$7.53$25.17$5.31
% of 52W HighCurrent price vs 52-week peak+38.8%+76.3%+96.7%+49.4%
RSI (14)Momentum oscillator 0–10055.348.160.261.3
Avg Volume (50D)Average daily shares traded25K252K2.3M194K
ALKS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

AEYE leads this category, winning 1 of 1 comparable metric.

Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).

MetricAIMD logoAIMDAinos, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcAEYE logoAEYEAudioEye, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$46.33$44.00
# AnalystsCovering analysts1528
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0001
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.5%0.0%
AEYE leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AEYE leads in 3 (Valuation Metrics, Total Returns).

Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...

AIMD vs DBVT vs ALKS vs AEYE: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is AIMD or DBVT or ALKS or AEYE a better buy right now?

For growth investors, AudioEye, Inc.

(AEYE) is the stronger pick with 14. 5% revenue growth year-over-year, versus -83. 0% for Ainos, Inc. (AIMD). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — AIMD or DBVT or ALKS or AEYE?

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.

9%, compared to -99. 4% for Ainos, Inc. (AIMD). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus AIMD's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — AIMD or DBVT or ALKS or AEYE?

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

06β versus Ainos, Inc. 's 2. 54β — meaning AIMD is approximately 140% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — AIMD or DBVT or ALKS or AEYE?

By revenue growth (latest reported year), AudioEye, Inc.

(AEYE) is pulling ahead at 14. 5% versus -83. 0% for Ainos, Inc. (AIMD). On earnings-per-share growth, the picture is similar: Ainos, Inc. grew EPS 53. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, AEYE leads at 10. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — AIMD or DBVT or ALKS or AEYE?

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -717. 0% for Ainos, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -667. 7% for AIMD. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — AIMD or DBVT or ALKS or AEYE?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is AIMD or DBVT or ALKS or AEYE better for a retirement portfolio?

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

06)). Ainos, Inc. (AIMD) carries a higher beta of 2. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, AIMD: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between AIMD and DBVT and ALKS and AEYE?

These companies operate in different sectors (AIMD (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AIMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 49%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

AEYE

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 46%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.